Novotinib
Tyrosine Kinase Inhibitor, indicated for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Therapeutic Area
Oncohematology
Active Ingredient
Nilotinib
Line
Hematology + Oncology
Dosage forms
50, 150 and 200 mg x 120 hard capsules
